Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNX-482 is a peptide toxin derived from the venom of the African tarantula *Hysterocrates gigas*. It functions as a potent and selective inhibitor of voltage-gated calcium channels, specifically the CaV2.3 subtype (R-type calcium channels), with an IC50 of 30 nM. Additionally, it exhibits potent inhibitory effects on A-type potassium currents, particularly Kv4.3 channels (IC50 < 3 nM), and to a lesser extent, Kv4.2 channels. Its mechanism of action involves binding to the voltage-sensing domains of these ion channels, thereby modulating their activation and gating kinetics. SNX-482 has been utilized as a research tool to investigate the roles of these specific ion channels in various physiological and pathological processes, including its antinociceptive properties observed in models of chronic neuropathic pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SNX-482.